Roche Reports the CHMP’s Positive Opinion of Vabysmo for Retinal Vein Occlusion (RVO)
Shots:
- The CHMP has granted a positive opinion to Vabysmo (faricimab) for treating visual impairment caused by macular edema secondary to retinal vein occlusion (RVO), based on P-III (BALATON & COMINO) studies
- The P-III studies (BALATON: n=553 & COMINO: n=729) compare Vabysmo vs aflibercept in BRVO & CRVO patients, respectively, administered with 6 monthly injections of either Vabysmo (6mg) or aflibercept (2mg) for the first 20wks, followed by Vabysmo (6mg, Q4M) with a treat-and-extend regimen at wks.24-72
- Studies depicted improved early & sustained visions with strong retinal drying and a well-tolerated safety profile aligning with prior trials
Ref: Roche | Image: Roche
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
